Last reviewed · How we verify
CinnaPoietin®
CinnaPoietin is an erythropoiesis-stimulating agent that mimics erythropoietin to stimulate red blood cell production.
CinnaPoietin is an erythropoiesis-stimulating agent that mimics erythropoietin to stimulate red blood cell production. Used for Anemia associated with chronic kidney disease, Chemotherapy-induced anemia, Anemia in patients with cancer.
At a glance
| Generic name | CinnaPoietin® |
|---|---|
| Also known as | Beta erythropoietin |
| Sponsor | Cinnagen |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology/Oncology |
| Phase | Phase 3 |
Mechanism of action
CinnaPoietin is a recombinant human erythropoietin (rHuEPO) analog developed by Cinnagen, a Iranian pharmaceutical company. It binds to erythropoietin receptors on erythroid progenitor cells in bone marrow, promoting their proliferation and differentiation into mature red blood cells. This mechanism is used to treat anemia associated with chronic kidney disease, cancer chemotherapy, and other conditions.
Approved indications
- Anemia associated with chronic kidney disease
- Chemotherapy-induced anemia
- Anemia in patients with cancer
Common side effects
- Hypertension
- Thromboembolism
- Headache
- Injection site reactions
- Pure red cell aplasia (rare)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |